yea, the initial pilot study consisted of only 7 patients in Turkey...so there's that, lol. The results were quite compelling though:
- Intraocular inflammation began to resolve in all 7 patients on Day 1, with a median time to first response of 4 days (range 1 to 14 days) - Complete resolution of retinal findings was achieved in 4 to 21 days (median 14 days) - Five out of 7 patients were in remission when they reached the Day 28 visit.
They have a strong balance sheet which should get them through all three Ph3 read-outs. The erosive osteoarthritis PoC data may offer an upside surprise in July/Aug time-frame plus any progress on the ultra-orphan indications could move the dial without having to risk the Eyeguard A binary.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.